Biotechnology

Empire Genomics & Molecular Instruments launch NISH, a fully automated system promising faster, clearer RNA-ISH results by preserving precious tissue samples.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

The Aesthetic Syndicate evolves into Manor, launching a national brand that fuses injectables with medically supervised GLP-1 therapy and holistic health.

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

With six new collaborations, the life science leader aims to tame data complexity and accelerate discovery by creating a single, integrated software ecosystem.

A new partnership aims to solve banking woes for the multi-billion-dollar peptide and IV therapy industries, long deemed 'too risky' by traditional finance.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

Recognized on the CB Insights AI 100 list, Rhino Federated Computing pioneers a new era of secure, decentralized AI for highly regulated industries.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

Diagnostic leader Bracco enters the cell therapy market with BubbleGen, a novel microbubble tech that promises to streamline complex manufacturing.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

A new alliance of 21 biotech firms aims to forge a national strategy, warning that America's long-held lead in medical innovation is under pressure.

With its 100th study launch and a perfect client retention rate, Atreo's agile RTSM platform is challenging the rigid, slow pace of traditional trial tech.